Patel Sushil 4

What Happened

• Sushil Patel, a director of Revolution Medicines (RVMD), exercised options to acquire 2,955 shares at $37.54 each (cost ≈ $110,931) on June 29, 2026, and executed multiple open-market sales that day disposing of 5,580 shares for aggregate proceeds of about $1,048,968. The transactions were reported on a Form 4 filed July 1, 2026.
• The activity is largely sales (routine monetization) following an option exercise; the filing also shows a conversion/derivative entry for 2,955 shares reported with $0 proceeds (documenting the derivative conversion).

Key Details

• Transaction date: June 29, 2026; Form 4 filed July 1, 2026 (timely filing).
• Option exercise: 2,955 shares acquired @ $37.54 each (≈ $110,931).
• Open-market sales: 5,580 shares sold in multiple trades for total proceeds ≈ $1,048,968.
• Sale price range (across multiple lots): approximately $182.93 to $192.64 per share; several lots reported as weighted-average prices per footnotes.
• Shares owned after transaction: not explicitly stated in the provided summary; filing notes holdings include 1,191 restricted stock units (RSUs).
• Notable footnotes: trades were executed pursuant to a 10b5-1 trading plan adopted March 30, 2026; several lots executed in multiple trades with weighted-average pricing reported; one derivative conversion line is marked as fully vested.
• Transaction codes: M = exercise/conversion of derivative; S = open-market sale.

Context

• For options-related activity: the insider exercised options (cash outlay of ~$110.9K) and conducted same-day open-market sales. This pattern is commonly used to cover exercise cost or diversify holdings but the filing itself does not state motivations.
• The trades were executed under an established 10b5-1 plan, which is a pre-set trading arrangement that can indicate the sales were pre-planned rather than opportunistic market timing.